Subscribe to RSS
DOI: 10.1055/s-2000-11207
Karl F. Haug Verlag in MVH Medizinverlage Heidelberg GmbH & Co. KG
Postoperative Strahlentherapie beim Mammakarzinom
Publication History
Publication Date:
31 December 2000 (online)
![](https://www.thieme-connect.de/media/dzo/200002/lookinside/thumbnails/10.1055-s-2000-11207-1.jpg)
Zusammenfassung
Eine adäquate postoperative Strahlentherapie senkt das lokoregionäre Rückfallrisiko nach Brustkrebsoperation auf etwa ein Drittel bis ein Fünftel des ohne Radiotherapie bestehenden Risikos. Das lokale Rezidiv stellt einen unabhängigen prognostischen Faktor dar. In den letzten Jahren gibt es zunehmend Hinweise darauf, daß die postoperative Radiotherapie durch die verbesserte lokoregionäre Tumorkontrolle auch einen signifikanten Einfluß auf die langfristigen Überlebensraten hat. Eine Strahlentherapie ist deshalb grundsätzlich bei hohem lokalem Rezidivrisiko indiziert, also nach allen brusterhaltenden Operationen und nach Mastektomie bei fortgeschrittenen Stadien (pT3-4 oder ausgedehnter LK-Befall). Die Risiken einer modernen Strahlentherapie sind gering.
Summary
An adequate postoperative radiation therapy reduces the locoregional recurrence risk after a breast cancer surgery to about one third to one fifth of the risk, which is present without radiotherapy. The local relapse is an independent prognostic factor. During the last years there has been an increasing number of hints, that the postoperative radiotherapy has a significant influence on the long-term survival rates due to an improved locoregional tumor control. Therefore, a radiation therapy is basically induced in the case of a large local relapse risk, i.e. after all surgeries which save the breast and after mastectomy in advanced stages (pT3-4 or extensive LC infestation). The risk of a modern radiation therapy is low.
Schlüsselwörter
Postoperative Strahlentherapie - lokoregionäre Tumorkontrolle - Überlebensraten - lokales Rezidivrisiko
Keywords
Postoperative radiation therapy - locoregional tumor control - survival rates - local relapse risk
Literatur
- 1 Borner M., Bacchi M., Goldhirsch A.. et al. . First isolated locoregional recurrence following mastectomy for breast cancer: Results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J. Clin. Oncol.. 1994; 12 2071-2077
- 2 Cuzick J., Stewart H., Rutquist L.. et al. . Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol.. 1994; 12 447-453
- 3 Dunst J.. Adjuvante Strahlentherapie beim operablen Mammakarzinom. Onkologe. (1) 205-213
- 4 Early Breast Cancer Trialists' Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992; 339 1-15
- 5 Fisher B., Anderson S., Fisher E. R.. et al. . Significance after ipsilateral breast tumor recurrence after lumpectomy. Lancet. 1991; 338 327-331
- 6 Fisher B., Anderson S., Redmond C. K.. et al. . Reanalysis and results after 12 years follow-up in a randomized trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med.. 1995; 333 1456-1461
- 7 Forrest A. P., Stewart H. J., Everington D.. et al. . Randomized controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. 1996; 348 708-713
- 8 Kemperman H., Borger J., Hart A.. et al. . Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer: The role of local recurrence. Eur. J. Cancer. 1995; 31-A 690-698
- 9 Levitt S. H., Aeppli D. M., Nierengarten M. E.. The importance of local control in the conservative treatment of breast cancer. Acta oncol.. 1995; 34 839-844
- 10 Liljegren G., Holmberg L., Adami H. O.. et al. . Sector resection with or without postoperative radiotherapy for stage I breast cancer: five year results of a randomized trial. J. Natl. Cancer Inst.. 1994; 86 717-722
- 11 Nixon A. J., Manola J., Gelman R.. et al. . No long-term increase in cardiac-related mortality after breast-conserving surgery and raiation therapy using modern techniques. J. Clin. Oncol.. 1998; 16 1374-1379
- 12 Overgaard M., Hansen P. S., Overgaard J.. et al. . Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant radiotherapy: . Danish Cancer Cooperative Group 82b Trial. N. Engl. J. Med.. 1997; 337 949-955
- 13 Sauer R.. Einfluss der lokalen Kontrolle auf das Gesamtüberleben nach brusterhaltender Therapie des Mammakarzinoms. Strahlenther. Onkol. 1996; 172 181-185
- 14 Veronesi U., Luini A., Galimberti V.. et al. . Conservation approaches for the management of stage I/II carcinoma of the breast. Milan Cancer Institute trials. World J. Surg.. 1994; 18 70-75
- 15 Whelan T., Clark R., Roberts R.. et al. . Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Int. J. Radiat. Oncol. Biol. Phys.. 1994; 30 11
1 Die Frage der Systemtherapie beim lokoregionären Rezidiv wird zur Zeit in der multizentrischen GBSG-Studie 6 geprüft. Informationen und Studienprotokoll sind erhältlich über die Koordinierungsstelle der GBSG: Dr. H. F: Rauschecker, Fax: (0 80 31) 38 13 67.
Korrespondenzadresse:
Prof. Dr. Jürgen Dunst
Martin-Luther-Universität Halle-WittenbergKlinik
für Strahlentherapie
Dryanderstr. 4-7
06097 Halle
Phone: 0345 557-43 10
Fax: 0345 557-43 33
Email: juergen.dunst@medizin.uni-halle.de